Search filters

Filters
Clear All

Phase

  • 5
  • 12
  • 14
  • 18
  • 6
  • 74
  • 62
  • 74

Found 74 Muscular Dystrophy trials

A listing of Muscular Dystrophy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …
18 years - 99 years
All genders
Phase 3
This is a phase 3, 56-week, multicenter, randomized, placebo controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). Subjects will be randomized to 1 of 2 treatment sequences: Sequence A: 0.5 g/kg IgPro20 for 24 weeks followed by 0.5 g/kg IgPro20 for 28 weeks or …
 Prospective 4D Computed Tomography Angiography Of The Bicuspid Aortic Valve Apparatus: A Comparison Of Bicuspid Aortic Valves With And Without Aortic Insufficiency
99 years or below
All genders
The purpose of this study is to characterize the differences in the aortic valve and aortic root anatomy in patients with BAVs in order to better understand the anatomical features that allow the BAV to function normally. With this information, surgeons and cardiologists will be better able to determine which …
99 years or below
All genders
Phase 2
Modification #2 Feb 15, 2021: Title of protocol changed and phase changed from phase 2 to phase 2b. Changes in timing of selected activities, addition of labs (ESR, coagulation tests), the PRO sub-study and a COVID related consent for remote monitoring. IB updated to Edition 5. Modification #1 May 2020: …
99 years or below
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …